Semisynthetic pyrrolizidine alkaloid antitumor agents by Zalkow, Leon Harry
GEORGIA INSTITUTE OF TECHNOLOGY 	 OFFICE OF CONTRACT ADMINISTRATION 
PROJECT ADMINISTRATION DATA SHEET 
     
ORIGINAL 111 REVISION NO. 	 
GTRC7igf 	DATE  2 / 16 / 87  
SchoolLfili 	Chemistry  
Project No./(Center No.) G-33 —T05 	R5479-5A0 
  
Project Director: 	Dr. Leon H. Zalkow 
  
     
Sponsor: DHHS/PHS/NIH/National Cancer Institute 
  
Agreement No. : Grant No. 5 RO1 CA31490-05 
Award Period: From 12/1/86 	To 	11/30/87  (Performance) 	2/29/88 Reports 
      
Sponsor Amount: 
Contract Value: $ 
Funded: $ 
New With This Change Total to Date 
$  197,935  
$ 197,935 
Cost Sharing No./(Center No.) 
 
Cost Sharing: $ 	  
 
Title: 	Semisynthetic Pyrrolizidine Alkaloid Antitumor Agents 
ADMINISTRATIVE DATA  
1) Sponsor Technical Contact: 
J.A.R. Mead. PH.D.  
OCA Contact E. Faith Gleason 	X-4820 
2) Sponsor Issuing Office: 
Ms. Catherine Walker (301)496-7227 
Division of Cancer Treatment 
National Cancer Institute 
5333 Westbard Ave. 
Bethesda, MD 20892 
(301) 496-8783  
Grant Management Officer 
National Cancer Institute 
National Institutes of Health 
5333 Westbard Ave. 
Bethesda, MD 20892 
Military Security Classification: 	N/A 	ONR Resident Rep. is ACO: 	 Yes 	X 	No 
(or) Company/Industrial Proprietary: Defense Priority Rating: 
RESTRICTIONS 
See Attached 	NTH Supplemental Information Sheet for Additional Requirements. 
  
Travel: Foreign travel must have prior approval — Contact OCA in each case. Domestic travel requires sponsor 
approval where total will exceed greater of $500 or 125% of approved proposal budget category. 
Equipment: Title vests with  GIT. No equipment may be purchased within the last 6 months of  
the Final year of an NIH grant.  
COMMENTS: 
COniLinuCet/0/7 e>c G "33 To 
    





Research Administrative Network 
Research Property Management 
mmilliESEUNimmimi■mm 
SPONSOR'S I.D. NO.  02•108• 001 • 87 • 006  
Procurement/GTRI Supply Services 	 GTRC 
Research Security Services 	 Library 
ContrectSupport.Dir;t0CA)(2P 	 Project File 
• • Other I. Lashley 
GEORGIA INSTITUTE OF TECHNOLOGY 	 OFFICE OF CONTRACT ADMINISTRATION 
 
SPONSORED PROJECT TERMINATION/CLOSEOUT SHEET 




       
Project No. G- 33 —T05 
  
SchooIRXM  Chemistry  
 
     
        
InCludes Subproject No.(s) N/A 
Project Director(s) L. H. Zalkow 
GTRC / IZCX 
  
rum DHHS/PHS/NIH/National Cancer Institute 
Ele Semisynthetic Pyrrolizidine Alkaloid Antitumor Agents 
fective Completion Date: 11/30/87 	(Performance)  2/29/88 	 (Reports) 
Grant/Contract Closeout Actions Remaining: 
None 
Final Invoice or Final Fiscal Report 
Closing Documents 
Final Report of Inventions 
Govt. Property Inventory & Related Certificate 
n Classified Material Certificate 
Other 
continues Project No.  G-33•T04 	Continued by Project No. G-33—T06 
COPIES TO: 
Project Director 	 Library 
Research Administrative Network 	 GTRC 
Research Property Management Research Communications (2) 
Accounting 	 Project File 
Procurement/GTRI Supply Services 	 Other 	Duane Hutchison 
Research Security Services 	 Angela DuBos e 
Reports Coordinator (OCA)_._ 	 Russ Embry 
Legal Services 
FORM OCA 69.285 
GRANT NUMBER 
SECTION IV 
PROGRESS REPORT SUMMARY 
PRINCIPAL INVESTIGATOR OR PROGRAM DIRECTOR 
Leon. H. Zalkow  
CA-31490-06 




TITLE OF PROJECT (Repeat title Shown in item 1 on first page) 
Semisynthetic Alkaloid Antitumor Agents  
(SEE INSTRUCTIONS) 
Dec. 1, 1987 Nov. 30, 1988 
1. There have been no changes in our objectives, specific aims or 
experimental design and methods. 
2. Studies conducted during current budget year: 
Using the 3P31 in vivo antitumor assay at NIH, until its discontinuance, 
we continued to accumulate structure-activity information which hopefully will 
ultimately lead to an explanation of the mechanism of action of these 
compounds and to the rational design of the most effective antitumor agent. 
Following are listed the compounds synthesized and submitted for screening 
during this period, and comparison with our best drug to date, namely NSC 
376359. NSC 612381 showed only marginal activity, suggesting that pare 
electron releasing groups on the phenyl ring are detrimental. This is 
consistent with a mechanistic explanation involving alkylation at the C9 
position by a biopolymer. NSC 610759 was found to be inactive, adding support 
to our in vitro evidence suggesting NSC 376359 is a DNA crosslinking agent, 
thus requiring two active functional groups (C7 & C9). NSC 610760 was toxic 
at 200 mg/Kg and inactive at lower doses. This is in contract to its 
excellent activity in the in vitro soft agar colony forming assay using A204 
human rhabdomyosarcoma cells. We believe this suggests that too good a 
leaving group at C7 can lead to a lack of discrimination when the drug acts as 
an electrophile. No in vivo results are yet available on the bifunctional 
compounds NSC 614643 and 614644. All of the above mentioned compounds are N-
oxides. Not unexpectedly, dihydroindicine N-oxide (NSC 600090), was found to 
be inactive, providing support for the assumption that the N-oxides are 
metabolically converted into the active pyrroles. Surprisingly, 
dihydroindicine (NSC 600089) was inactive but toxic at doses from 650 mg/Kg 
down to 162 mg/Kg (test reconfirmed), whereas the isomeric 7-( -) - 
 trachelanthylplatynecine (NSC 610331) was both inactive and non-toxic). This 
strange toxicity of NSC 600089 remains unexplained (indicine itself is non-
toxic at very high dose!). A number of other compounds have been synthesized 
and are at various stages of development for submission to the new NCI in 
vitro screen. 
In the in vitro soft agar colony forming assay using A204 human 
rhabdomyosarcoma cells, NSC 614644 showed comparable activity to NSC 376359, 
suggesting it could be considered a prodrug. The corresponding free base EGK-
24 was even more active, being considerably more active than the free base 
(EGK-25) of NSC 376359. The carbamate N-oxide NSC 614643, and its free EGK-20 
were somewhat lees active than NSC 614644. Several naturally occurring 
pyrrolizidine alkaloids were screened, but none were comparable to the 
semisynthetic compounds containing an aromatic ring in the side chain. We 
have developed a new and novel synthesis of supinidine from retronecine which 
will allow us to determine whether it is necessary to have a leaving group at 
C-7. 
During this period we have spent considerable time developing the 
procedures for determining the partition coefficients of the drugs (N-oxides 
have not previously been measured), and their corresponding free bases, and in 
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measuring the kinetics of the alkylation reactions of the pyrroles, chemically 
derived from the drug N-oxides, with 4-p-nitrobenzylpyridine. These 
experimental procedures have been developed using considerable amounts of 
automation and data on a number of compounds have been obtained. The purpose 
of this investigation is to obtain physical-chemical information on the 
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Studies have been conducted on DNA crosslinking and DNA strand breaks 
with the pyrrolizidine alkaloids (PAs) incubated with tumor cells using the 
DNA alkaline elution assay. A small number of DNA strand breaks were produced 
by indicine N-oxide. This could be due to formation of oxygen radicals or to 
other damage to the DNA. Single strand breaks have not been seen with other 
PAs. DNA crosslinking has been seen with the NSC-376359 and EGK-25, by the 
diester NSC-610760 and its free base and by indicine, but not indicine N-
oxide. The PAs are not particularly strong crosslinking agents compared with 
other crosslinking agents and good dose-response curves are not seen. There 
appear to be two clasess of PAs, those that are moderate crosslinkers with 
considerable in vitro cytotoxicity, where the N-oxide is more active than the 
base, and non-crosslinkers where the base is more active than the N-oxide. 
Based on our hypothesis that PA N-oxides are activated to pyrrolic 
alkylating intermediates by an iron catalyzed reaction, we have been looking 
at the effect of iron chelating agents on the cytotoxicity of PAs to tumor 
cells in culture. We have so far not seen an effect of the iron chelators on 
cytotoxicity. Other metal ions may, however, catalyze the oxidation of PAs. 
We have continued our studies to develop an animal model for the 
hepatotoxicity of antitumor PAs. We have been unable to obtain consistent 
signs of hepatotoxicity with indicine N-oxide administered, even at toxic 
doses i.v. to dogs, rats or mice. When indicine N-oxide is administered p.o. 
to mice hepatic necrosis is seen. This may form the model for hepatic 
toxicity and work is continuing with other PAs administered p.o. 
Publications: Structure of 2a-Bromo-18,78-epoxytrachelanthamidine: A New 
Heterocyclic Ring System. Glinski, J. A.; VanDerveer, D.; Zalkow, L. H. Acta 
Cryst. 1986, C42, 1239-1242. 
